ScreenerHero

GNS Genus plc

LSE · GB · Healthcare · Biotechnology · genusplc.com
2126.00GBp-0.84%Mkt Cap: 1.53B $P/E: 5.00

Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Gen…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap1.53B USD
Enterprise Value1.61B USD
Revenue (TTM)715.33M USD
Gross Profit715.33M USD
Net Income (TTM)310.11M USD
Revenue/Share9.96 GBp
Last Price2126.00 GBp
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)5.00
P/E (Forward)18.37
PEG—
EV/EBITDA14.31
EV/Revenue2.25
P/S2.16
P/B1.85
EPS (TTM)4.25
EPS (Forward)1.17
52W Range
1943.0014% of range3220.00
52W High3220.00 GBp
52W Low1943.00 GBp
Profitability
Gross Margin100.00%
Oper. Margin9.67%
EBITDA Margin15.73%
Profit Margin43.35%
ROE45.95%
ROA5.21%
Growth
Revenue Growth-4.10%
Earnings Growth1341.70%
Cash Flow & Leverage
Operating CF73.04M USD
CapEx (TTM)20.22M USD
FCF Margin7.51%
FCF Yield3.51%
Net Debt69.35M USD
Net Debt/EBITDA0.62
Balance Sheet
Debt/Equity0.56
Current Ratio2.21
Quick Ratio1.42
Book Value/Sh11.60 GBp
Cash/Share0.66 GBp
Dividends
Fwd Div Rate0.33 GBp
Trail. Div Rate0.35 GBp
Div. Yield1.53%
5Y Avg Yield1.28%
Payout Ratio45.07%
Ex-Div DateNov 12, 2026
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3039.85 GBp
Upside (mean)+43.0%
Target Range2350.00 GBp – 3700.00 GBp
2350.00+43.0% to mean3700.00
# Analysts13
Ownership
Shares Out.66.15M
Float65.09M
Insiders0.76%
Institutions72.99%
Technical
SMA 502227.24 (-4.5%)
SMA 2002450.20 (-13.2%)
Beta0.90
S&P 52W Chg14.58%
Avg Vol (30d)180.27K
Avg Vol (10d)237.08K
Technical Indicators
RSI (14)43.7
MACD-26.1810
MACD Signal-29.2515
MACD Hist.+3.0705
BB Upper2257.57 GBp
BB Middle2150.40 GBp
BB Lower2043.23 GBp
BB Width9.97%
ATR (14)72.79 GBp
Vol Ratio (20d)0.89x